Health Canada
- Status: approved
🇨🇦 Mixtard 30:70 Novonordisk® twice daily in Canada
Mixtard 30:70 Novonordisk® twice daily (Mixtard 30:70 Novonordisk® twice daily) regulatory status in Canada.
Marketing authorisation
Mixtard 30:70 Novonordisk® twice daily in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Mixtard 30:70 Novonordisk® twice daily approved in Canada?
Yes. Health Canada has authorised it.
Who is the marketing authorisation holder for Mixtard 30:70 Novonordisk® twice daily in Canada?
Hospital Universitario Central de Asturias is the originator. The local marketing authorisation holder may differ — check the official source linked above.